Founded in 1999, CogState listed on the Australian Stock Exchange in February 2004. (ASX:CGS)
CogState specializes in the development and commercialization of technologies for the measurement of cognition.
CogState's products address a variety of markets, the primary market being cognitive testing in clinical trials, where the technologies are used to quantify the effect of disease and of drugs, devices or other interventions on human subjects participating in clinical trials conducted by pharmaceutical, biotechnology, nutraceutical and functional food companies.
Other markets include academic research, concussion management for athletes, memory monitoring and fitness-for-duty testing for workplaces.
CogState began selling tests of cognition into the clinical trials market in 2004 and since that time CogState has secured agreements with international organisations including Pfizer, GlaxoSmithKline, Abbot, Merck, Lundbeck, The Centers for Disease Control (USA), ALZA Corporation (a member of the Johnson and Johnson group) and Organon USA.
CogState is continuing to increase its market share of the clinical trials market having achieved significant revenue growth across the last 3 years. CogState expects sales to continue to grow as it expands its activities in the USA and Europe.